Cerberus Telecom Acquisition Corp Announces New Date for Special Meeting of Shareholders and Additional Sources of Liquidity for Post-Closing Public Company – Consumer Electronics Net consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, May 25, 2021 /PRNewswire/ Illuminare Biotechnologies, a clinical-stage biotechnology company, announced that its novel nerve imaging agent, Illuminare-1, has been granted Fast Track Designation by the US Food and Drug Administration (FDA). Illuminare-1 is a small molecule, myelin binding agent, the company is developing as a surgical adjunct to improve the visualization and delineation of critical nerve structures intra-operatively. The ability to locate and delineate nerves in real time during surgical procedures may avoid serious, and potentially permanent, unintended nerve injury. The first human clinical trial of Illuminare-1 is scheduled to begin in 2Q 2021 at Memorial Sloan Kettering Cancer Center (MSK) in patients undergoing robot-assisted radical prostatectomy.
UpdatedWed, May 5, 2021 at 9:02 am ET
Replies(2)
Danvers residents went to the polls on Tuesday after two weeks of mail-in and early voting. Find out what they decided. (Patch Graphics)
DANVERS, MA Gardner Trask claimed victory in his quest for a sixth term on the Danvers Select Board and Matthew Duggan earned the second Select Board seat, while Robin Doherty and Alice Campbell won the two School Committee seats up for grabs, according to unofficial results Tuesday night.
Trask faced three other challengers in his bid for another three years.
Trask tallied 1,444 votes (25.4 percent), with Duggan second at 1,177 (20.7 percent). Timothy Donahue third at 1,093 (19.3 percent) and Richard Bettencourt fourth at 1,085 (19.1 percent. There were 865 blanks and 10 write-ins.
KPS Capital Partners To Acquire EMEA Food And Consumer Packaging Business From Crown Holdings
Leading European packaging business to become independent company
Crown holdings, inc. To retain 20% ownership interest
New company to focus on growth in food and consumer products markets
New York, NY /PRNewswire/ - KPS Capital Partners, LP ( KPS ) today announced that it has signed a definitive agreement to acquire the Europe, Middle East and Africa food, aerosol and promotional packaging business (the EMEA Food and Consumer Packaging Business or the Company ) from Crown Holdings, Inc. (NYSE: CCK, Crown ) for €2.25 billion (approximately $2.7 billion). Crown will retain 20% ownership of the Company. The transaction is expected to close in the third quarter of 2021 and is subject to customary closing conditions and approvals.
Share this article
Share this article
NEW YORK, April 15, 2021 /PRNewswire/ The US Food and Drug Administration (FDA) has approved Illuminare-1, a small molecule, myelin binding agent, for their Investigational New Drug Application (IND). Illuminare-1 is being developed as a surgical adjunct to improve the visualization and delineation of critical nerve structures intra-operatively in real time with the aim of avoiding serious, and potentially permanent, unintended nerve injury. The first-in human clinical trial will be conducted at Memorial Sloan Kettering Cancer Center (MSK), along with collaborators from Illuminare Biotechnologies, in patients undergoing robot-assisted radical prostatectomy.
Surgery plays a prominent role as first line treatment across many medical conditions. The ultimate goal of surgery is to repair or remove damaged and/or diseased tissue while preserving vital structures, including nerves. Even with advanced surgical techniques, unintended nerve injury re